These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33211212)

  • 81. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Eastell R; Chen P; Saag KG; Burshell AL; Wong M; Warner MR; Krege JH
    Bone; 2010 Apr; 46(4):929-34. PubMed ID: 20060078
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
    N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
    Takeda S; Kaneoka H; Saito T
    Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
    Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Bone; 2014 Sep; 66():26-30. PubMed ID: 24909538
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice.
    Soen S; Umemura T; Ando T; Kamisaki T; Nishikawa M; Muraoka R; Ikeda Y; Takeda K; Osawa M; Nakamura T
    J Bone Miner Metab; 2017 Jul; 35(4):419-427. PubMed ID: 27565972
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
    Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
    J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.
    Zhao Y; Xue R; Shi N; Xue Y; Zong Y; Lin W; Pei B; Sun C; Fan R; Jiang Y
    Osteoporos Int; 2016 Nov; 27(11):3309-3317. PubMed ID: 27245056
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
    Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
    J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
    Fujita T; Fukunaga M; Itabashi A; Tsutani K; Nakamura T
    Calcif Tissue Int; 2014 Feb; 94(2):170-5. PubMed ID: 23963633
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis.
    Etani Y; Ebina K; Hirao M; Kitaguchi K; Kashii M; Ishimoto T; Nakano T; Okamura G; Miyama A; Takami K; Goshima A; Kanamoto T; Nakata K; Yoshikawa H
    Bone; 2020 Oct; 139():115525. PubMed ID: 32645445
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis.
    Nakamura T; Tsujimoto M; Hamaya E; Sowa H; Chen P
    J Bone Miner Metab; 2012 May; 30(3):321-5. PubMed ID: 21938382
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
    Yuan C; Liang Y; Zhu K; Xie W
    J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.